Table 4. Uni- and multivariate analyses of recurrence.
|
Univariate analysis |
Multivariate analysis |
||||||
|---|---|---|---|---|---|---|---|
| n (%) | OR (95% CI) | P value | HR | 95% CI | P value | ||
| Sex | 0.02 | ||||||
| Female | 166 (52) | 1.42 (1.07–1.89) | — | — | 0.21 | ||
| Male | 316 (60.7) | ||||||
| Mutation | <0.0001 | ||||||
| WT | 259 (54.8) | — | — | — | — | ||
| EGFR | 27 (26.2) | ||||||
| KRAS | 196 (74) | ||||||
| Mutation | <0.0001 | ||||||
| KRAS G12V | 89 (98.9) | 81.5 (11.3–588.06) | 0.01 | 0.001–0.08 | <0.0001 | ||
| Non-KRAS G12V | 392 (52.2) | ||||||
| Nodal status | <0.0001 | ||||||
| N0 | 208 (50) | 1.81 (1.38–2.39) | — | — | 0.53 | ||
| N+ | 274 (64.5) | ||||||
| pT | 0.01 | ||||||
| 1 | 107 (50.2) | — | — | 0.88 | |||
| 2 | 211 (60.1) | ||||||
| 3 | 138 (62.4) | ||||||
| 4 | 26 (46.4) | ||||||
| Angioinvasion | 0.007 | ||||||
| Yes | 208 (63.2) | 1.49 (1.12–1.98) | — | — | 0.07 | ||
| No | 274 (53.5) | ||||||
| Smoking habit | <0.0001 | ||||||
| Never | 68 (40) | — | — | 0.28 | |||
| Past | 198 (62.5) | ||||||
| Current | 216 (61) | ||||||
| Neo-adjuvant treatment | 0.88 | ||||||
| Yes | 187 (38.8) | 0.97 (0.73–1.28) | — | — | — | ||
| No | 295 (61.2) | ||||||
| Type of neo-adjuvant treatment | 0.25 | ||||||
| Chemo. | 140 (54.5) | 1.28 (0.65–2.12) | — | — | — | ||
| RT chemo. | 47 (65.3) | ||||||
| Adjuvant treatment | <0.0001 | ||||||
| Yes | 280 (64.5) | 1.84 (1.4–2.43) | — | — | 0.33 | ||
| No | 202 (49.6) | ||||||
| Type of adjuvant treatment | 0.33 | ||||||
| RT | 6 (66.7) | — | — | — | — | ||
| Chemo. | 241 (64.3) | ||||||
| RT chemo. | 33 (66) | ||||||
| Type of resection | <0.0001 | ||||||
| Seg. | 23 (59) | — | — | — | 0.15 | ||
| Lob. | 427 (57.9) | ||||||
| Bi-lob. | 1 (5.9) | ||||||
| Pneum. | 31 (64.6) | ||||||
| Skip N | 0.46 | ||||||
| Yes | 7 (38.9) | 0.57 (0.19–1.69) | — | — | — | ||
| No | 30 (52.6) | ||||||
| Microscopic N | 0.9 | ||||||
| Yes | 23 (62.2) | 0.89 (0.45–1.8) | — | — | — | ||
| No | 251 (64.7) | ||||||
| Number of N2 stations involved | 0.94 | ||||||
| 1 | 68 (52.7) | 1.09 (0.54–2.23) | — | — | — | ||
| 2 | 22 (55) | ||||||
| R0 | 473 (57.1) | 1.69 (0.52–5.23) | 0.55 | — | — | — | |
| R1 | 9 (69.2) | ||||||
Abbreviations: CI=confidence interval; chemo.=chemotherapy; HR=hazard ratio; OR=odds ratio; RT=radiotherapy.
Because KRAS G12V and mutational status correlated, only KRAS G12V status was entered in the multivariate model. Non-KRAS G12V included wild-type, EGFR mutants and KRAS non-G12V patients.